Managing Drug Interactions in the
Treatment of HIV-Related
Tuberculosis
Table 3. Recommendations
for Coadministering Antiretroviral
Drugs with
RIFABUTIN – 2007
Non-nucleoside reverse-transcriptase inhibitors |
|
Antiretroviral
dose change |
Rifabutin dose change |
Comments |
Efavirenz |
No change |
to 450-600 mg (daily or intermittent) |
Rifabutin
AUC ¯ by 38%. Effect of efavirenz + protease
inhibitor(s) on rifabutin concentration has not been studied. Efavrirenz
should not be used during the 1st trimester of pregnancy. |
Nevirapine |
No change |
No change (300 mg daily or thrice-weekly) |
Rifabutin and nevirapine AUC not significantly changed. |
Delavirdine |
Rifabutin
and delavirdine should not be used together |
Delavirdine
AUC ¯ by 80%; rifabutin AUC
by 100%. |
Etravirine |
No change |
No change (300 mg daily or thrice-weekly) |
No clinical experience; etravirine Cmin
¯ by 45%, but this was not thought to warrant a change
in dose |
Single
protease inhibitors |
|
Antiretroviral dose change |
Rifabutin dose change |
Comments |
fos-Amprenavir |
No change |
¯ to 150 mg/day
or
300 mg 3x/week |
No
published clinical experience |
Atazanavir |
No change |
¯ to 150 mg every other day or 3x/week |
No
published clinical experience. Rifabutin AUC
by 250% |
Indinavir |
1000 mg every 8 hours |
¯ to 150 mg/day
or
300 mg 3x/week |
Rifabutin
AUC by 170%; indinavir concentrations
¯ by 34% |
Nelfinavir |
No change |
¯ to 150 mg/day
or
300 mg 3x/week |
Rifabutin
AUC by 207%; insignificant change in nelfinavir concentration |
Dual protease inhibitor combinations |
|
Antiretroviral dose change |
Rifabutin dose change |
Comments |
Lopinavir / ritonavir (Kaletra
ä) |
No change |
¯ to 150 mg every other day or 3x/week |
Rifabutin
AUC by 303%; 25-O-des-acetyl rifabutin
AUC by 47.5 fold. |
Ritonavir (any dose) with saquinavir,
indinavir, amprenavir, fos-amprenavir, atazanavir, tipranavir or darunavir |
No change |
¯ to 150 mg every other day or 3x/week |
Rifabutin
AUC and 25-O-des-acetyl rifabutin AUC
,
by varying degrees. |
CCR-5
receptor antagonists |
Maraviroc |
No change |
No
change |
No
clinical experience; a significant interaction is unlikely, but this has
not yet been studied |
Integrase inhibitors |
Raltegravir |
No change |
No
change |
No
clinical experience; a significant interaction is unlikely, but this has
not yet been studied |
|
Last Reviewed: 05/18/2008 Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Back to Top of Page
You will need Adobe Acrobat Reader
v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat Reader.
If you have difficulty accessing any
material on the DTBE Web site because of a disability, please contact
us in writing or via telephone and we will work with you to make the information
available.
Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: tbinfo@cdc.gov
|
Home | Site Map
| Contact Us
Accessibility
| Privacy Policy Notice |
FOIA
| USA.gov
CDC Home |
Search |
Health Topics A-Z
Centers for Disease Control & Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination Please send comments/suggestions/requests to: CDCINFO@cdc.gov
|